Literature DB >> 26242477

The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Corinne Beinat1, Samuel D Banister, Marco Herrera, Vivian Law, Michael Kassiou.   

Abstract

Homomeric α7 nicotinic acetylcholine receptors (α7 nAChRs) have implications in the regulation of cognitive processes such as memory and attention, and have shown promise as a therapeutic target for the treatment of the cognitive deficits associated with schizophrenia. Multiple α7 nAChR agonists have entered human trials; however, unfavorable side effects and pharmacokinetic issues have hindered the development of a clinical α7 nAChR agonist. Currently, EVP-6124 is in phase III clinical trials, and several other α7 nAChR agonists (GTS-21 and AQW051) are in earlier stages of development. This review will summarize the recent advances and failures of α7 nAChR agonists in clinical trials for the treatment of the aforementioned pathology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26242477     DOI： 10.1007/s40263-015-0260-0

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  92 in total

1.  Neuroscience. Deconstructing schizophrenia.

Authors:  Constance Holden
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

Review 2.  Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Authors:  Karin R Tietje; David J Anderson; R Scott Bitner; Eric A Blomme; Paul J Brackemeyer; Clark A Briggs; Kaitlin E Browman; Dagmar Bury; Peter Curzon; Karla U Drescher; Jennifer M Frost; Ryan M Fryer; Gerard B Fox; Jens Halvard Gronlien; Monika Håkerud; Earl J Gubbins; Sabine Halm; Richard Harris; Rosalind J Helfrich; Kathy L Kohlhaas; Devalina Law; John Malysz; Kennan C Marsh; Ruth L Martin; Michael D Meyer; Angela L Molesky; Arthur L Nikkel; Stephani Otte; Liping Pan; Pamela S Puttfarcken; Richard J Radek; Holly M Robb; Eva Spies; Kirsten Thorin-Hagene; Jeffrey F Waring; Hilde Ween; Hongyu Xu; Murali Gopalakrishnan; William H Bunnelle
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

Authors:  A Olincy; D A Young; R Freedman
Journal:  Biol Psychiatry       Date:  1997-07-01       Impact factor: 13.382

4.  Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.

Authors:  C A Briggs; D J Anderson; J D Brioni; J J Buccafusco; M J Buckley; J E Campbell; M W Decker; D Donnelly-Roberts; R L Elliott; M Gopalakrishnan; M W Holladay; Y H Hui; W J Jackson; D J Kim; K C Marsh; A O'Neill; M A Prendergast; K B Ryther; J P Sullivan; S P Arneric
Journal:  Pharmacol Biochem Behav       Date:  1997 May-Jun       Impact factor: 3.533

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 6.  Review and management of clozapine side effects.

Authors:  D D Miller
Journal:  J Clin Psychiatry       Date:  2000       Impact factor: 4.384

Review 7.  The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).

Authors:  W R Kem
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

Review 8.  Neuronal nicotinic receptors: from structure to pathology.

Authors:  C Gotti; F Clementi
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

9.  DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.

Authors:  Heidi C O'Neill; Kate Rieger; William R Kem; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2003-05-21       Impact factor: 4.530

10.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853
View more
  27 in total

1.  Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.

Authors:  Ricardo Alvarez-Jimenez; Ellen P Hart; Samantha Prins; Marieke de Kam; Joop M A van Gerven; Adam F Cohen; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2018-02-20       Impact factor: 4.335

Review 2.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.

Authors:  Jason Smucny; Jason R Tregellas
Journal:  J Psychopharmacol       Date:  2017-04-26       Impact factor: 4.153

3.  A Computational Analysis of the Factors Governing the Dynamics of α7 nAChR and Its Homologs.

Authors:  Alican Gulsevin; Jens Meiler; Nicole A Horenstein
Journal:  Biophys J       Date:  2020-09-16       Impact factor: 4.033

4.  Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness.

Authors:  Thomas Papouin; Jaclyn M Dunphy; Michaela Tolman; Kelly T Dineley; Philip G Haydon
Journal:  Neuron       Date:  2017-05-04       Impact factor: 17.173

5.  Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.

Authors:  Randi Melissa Schuster; Gladys N Pachas; Luke Stoeckel; Corinne Cather; Mireya Nadal; David Mischoulon; David A Schoenfeld; Haiyue Zhang; Christine Ulysse; Elisabeth B Dodds; Sara Sobolewski; Vicenta Hudziak; Ailish Hanly; Maurizio Fava; A Eden Evins
Journal:  J Clin Psychopharmacol       Date:  2018-08       Impact factor: 3.153

Review 6.  GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.

Authors:  Meng-Yi Xu; Albert H C Wong
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

7.  PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans.

Authors:  Ansel T Hillmer; Songye Li; Ming-Qiang Zheng; Matthias Scheunemann; Shu-Fei Lin; Nabeel Nabulsi; Daniel Holden; Richard Pracitto; David Labaree; Jim Ropchan; Rodrigo Teodoro; Winnie Deuther-Conrad; Irina Esterlis; Kelly P Cosgrove; Peter Brust; Richard E Carson; Yiyun Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-24       Impact factor: 9.236

8.  Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture.

Authors:  Dingquan Zou; Man Luo; Zhenying Han; Lei Zhan; Wan Zhu; Shuai Kang; Chen Bao; Zhao Li; Jeffrey Nelson; Rui Zhang; Hua Su
Journal:  Mol Neurobiol       Date:  2016-12-02       Impact factor: 5.590

Review 9.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

Review 10.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.